Insight Molecular DiagnosticIMDX
13F holders, Q1 2025 (March 31)At the end of Q1 2025, 29 institutions reported holding Insight Molecular Diagnostic (IMDX) in their 13F filings, up 3 from Q4 2024. 8 opened new positions and 5 sold out. The largest holders were Broadwood Capital Inc. ($34.9M), AWM Investment Company, Inc. ($8.6M) and Pura Vida Investments, LLC ($2.9M). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Insight Molecular Diagnostic
- Filed as
- ONCOCYTE CORP (Q1 2025)
- CUSIP
- 68235C206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $411K |
| Exits | 5 | $61K |
All 13F filers, Q4 2024 → Q1 2025: 7,718,560 shares bought and 39,342 shares sold, net +7,679,218 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 29 holders
| Broadwood Capital Inc. | 2.83% | Add +82.7% | 11,410,100 | $34.9M |
| AWM Investment Company, Inc. | 1.19% | Add +263.8% | 2,822,530 | $8.6M |
| Pura Vida Investments, LLC | 21.17% | Add +44.7% | 947,134 | $2.9M |
| Vanguard Group Inc. | 0.00% | Add +9.6% | 265,457 | $812K |
| Geode Capital Management, LLC | 0.00% | Add +15.9% | 158,907 | $486K |
| BlackRock, Inc. | 0.00% | Reduce -0.5% | 79,585 | $244K |
| Wealthedge Investment Advisors, LLC | 0.10% | Add +40.3% | 73,971 | $226K |
| Morgan Stanley | 0.00% | No change | 61,708 | $189K |
| Citadel Advisors | 0.00% | New | 48,784 | $149K |
| Susquehanna International Group, LLP | 0.00% | New | 44,806 | $137K |
| FNY Investment Advisers, LLC | 0.07% | Reduce -20.7% | 39,172 | $119K |
| Northern Trust Corp. | 0.00% | Add +67.7% | 29,069 | $89K |
| State Street Corp. | 0.00% | No change | 19,554 | $60K |
| SG Americas Securities, LLC | 0.00% | New | 16,585 | $51K |
| Millennium Management | 0.00% | New | 13,404 | $41K |
| HRT Financial LP | 0.00% | New | 10,149 | $31K |
| UBS Group AG | 0.00% | Reduce -2.2% | 2,654 | $8K |
| Osaic Holdings, Inc. | 0.00% | Add +594.0% | 1,263 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -73.0% | 1,164 | $4K |
| ORG Partners LLC | 0.00% | New | 450 | $1K |
| Bank of America Corp. | 0.00% | Add +1.1% | 441 | $1K |
| Wilmington Savings Fund Society, FSB | 0.00% | No change | 250 | $765 |
| BNP Paribas Financial Markets | 0.00% | No change | 208 | $636 |
| SBI Securities Co., Ltd. | 0.00% | No change | 185 | $566 |
| JPMorgan Chase & Co. | 0.00% | Reduce -13.8% | 168 | $514 |
| Larson Financial Group LLC | 0.00% | New | 125 | $383 |
| Piscataqua Savings Bank | 0.00% | No change | 25 | $76 |
| Albion Financial Group | 0.00% | No change | 7 | $22 |
| Wells Fargo & Company | 0.00% | New | 3 | $9 |
"% of holder's portfolio" is IMDX's weight in each manager's 13F, not the share of Insight Molecular Diagnostic the manager owns.